Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial

OBJECTIVE: To assess mexiletine's long-term safety and effect on 6-minute walk distance in a well-defined cohort of patients with myotonic dystrophy type 1 (DM1). METHODS: We performed a randomized, double-blind, placebo-controlled trial of mexiletine (150 mg 3 times daily) to evaluate its effi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurology
Main Authors: Heatwole, Chad, Luebbe, Elizabeth, Rosero, Spencer, Eichinger, Katy, Martens, William, Hilbert, James, Dekdebrun, Jeanne, Dilek, Nuran, Zizzi, Christine, Johnson, Nicholas, Puwanant, Araya, Tawil, Rabi, Schifitto, Giovanni, Beck, Christopher A., Richeson, J. Franklin, Zareba, Wojciech, Thornton, Charles, McDermott, Michael P., Moxley, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7905778/
https://ncbi.nlm.nih.gov/pubmed/33046619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000011002
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados